Welcome to our dedicated page for Immucell SEC filings (Ticker: ICCC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImmuCell filings document material events and governance matters for an animal health biologics company built around First Defense. Form 8-K reports record preliminary and annual financial results, board retirements and appointments, senior-officer employment agreements, and settlement of claims tied to a prior development services and commercial supply agreement.
Definitive proxy materials cover director matters, board oversight, executive compensation, and equity-award disclosures. The filing record also includes exhibits with company press releases addressing product sales, financial condition, strategic focus, and related operating updates.
ImmuCell Corporation entered into a Loan Agreement and Promissory Note with Maine Community Bank for total loan proceeds of $2,327,119 at a fixed interest rate of 6.5% per annum. The proceeds were used to pay off an existing Maine Community Bank loan with an outstanding balance of $1,525,852 bearing interest at 7% and a Finance Authority of Maine loan with an outstanding balance of $768,209 bearing interest at 8%, effectively consolidating those obligations into a single loan.
The new loan is secured by a security interest in substantially all of the Company’s assets, and the lender may accelerate repayment if the Company fails to make timely payments or otherwise comply with the loan terms. The Loan Agreement and Promissory Note are filed as Exhibits 10.1 and 10.2, and a related press release is filed as Exhibit 99.1.
ImmuCell Corporation (NASDAQ:ICCC) filed an 8-K announcing the initiation of a CEO succession planning process. The filing discloses that current President and CEO Michael F. Brigham will be part of this transition. The company has begun searching for new leadership, though no specific timeline was provided. This represents a significant corporate governance development for ImmuCell, as leadership transitions can materially impact company strategy and operations.